SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

NEXT STORY
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
PREV STORY
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

eFFECTOR Announces Appointment of John W. Smither to its Board of Directors

SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in ...

author_avatar
NASDAQ Market News

Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 – a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics

ALG.APV-527 Engineered to Engage the Immune System for the Potential Treatment of Multiple Solid ...

author_avatar
NASDAQ Market News

Genmab meddeler, at der vil blive præsenteret data vedrørende daratumumab på 2016-årsmødet i ASCO

Selskabsmeddelelse Mundtlig præsentation på plenum-session om data fra fase III daratumumab-studiet Castor Poster præsentation ...

author_avatar
NASDAQ Market News